Department of Urology, Faculty of Medicine and Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Jpn J Clin Oncol. 2019 May 1;49(5):421-425. doi: 10.1093/jjco/hyz017.
The Tumor-Node-Metastasis (TNM) staging system, jointly developed by the American Joint Commission on Cancer (AJCC) and the Union for International Cancer Control (UICC), is widely employed in clinical practice and research on patients with cancer. The definitions of TNM classification have recently been changed, improving patient stratification for management and prognosis. As the feature of new editions, biomarkers which are necessary for the stratification of patients are included to adapt for personalized medicine. Although it would be ideal for the AJCC and UICC have identical TNM staging systems, there are some differences between these two publications. In this review, we introduce the significant changes and differences in the eighth edition of the AJCC and UICC TNM staging systems for urologic cancers and summarize the evidence supporting these changes.
肿瘤-淋巴结-转移(TNM)分期系统由美国癌症联合委员会(AJCC)和国际抗癌联盟(UICC)共同制定,广泛应用于癌症患者的临床实践和研究中。TNM 分类的定义最近已经发生了变化,这改善了患者管理和预后的分层。作为新版本的特点,纳入了用于患者分层的生物标志物,以适应个体化医学。尽管 AJCC 和 UICC 拥有相同的 TNM 分期系统是理想的,但这两个出版物之间仍存在一些差异。在这篇综述中,我们介绍了 AJCC 和 UICC 泌尿生殖系统癌症第八版 TNM 分期系统的重大变化和差异,并总结了支持这些变化的证据。